Anti-MRSA agent 27, with the CAS number 23750-73-4, is a synthetic compound developed for its antibacterial properties, particularly against methicillin-resistant Staphylococcus aureus (MRSA). This compound belongs to a class of agents designed to combat antibiotic resistance, showcasing efficacy in inhibiting bacterial growth. Its mechanism of action typically involves disrupting bacterial cell wall synthesis or interfering with essential metabolic pathways, making it a valuable candidate in the fight against resistant strains of bacteria. The compound may exhibit characteristics such as moderate to high solubility in organic solvents, stability under various pH conditions, and a specific spectrum of activity against Gram-positive bacteria. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its therapeutic potential and safety profile. Research into Anti-MRSA agent 27 continues to explore its effectiveness, potential side effects, and optimal usage in clinical settings, contributing to the ongoing efforts to address antibiotic resistance in healthcare.

Anti-MRSA agent 27

23750-73-4: Anti-MRSA agent 27, with the CAS number 23750-73-4, is a synthetic compound developed for its antibacterial properties, particularly against methicillin-resistant Staphylococcus aureus (MRSA). This compound belongs to a class of agents designed to combat antibiotic resistance, showcasing efficacy in inhibiting bacterial growth. Its mechanism of action typically involves disrupting bacterial cell wall synthesis or interfering with essential metabolic pathways, making it a valuable candidate in the fight against resistant strains of bacteria. The compound may exhibit characteristics such as moderate to high solubility in organic solvents, stability under various pH conditions, and a specific spectrum of activity against Gram-positive bacteria. Additionally, its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are crucial for determining its therapeutic potential and safety profile. Research into Anti-MRSA agent 27 continues to explore its effectiveness, potential side effects, and optimal usage in clinical settings, contributing to the ongoing efforts to address antibiotic resistance in healthcare.

Anti-MRSA agent 27 (compound 4a) is a potent antimicrobial agent against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 0.0975 μmol/L. It effectively disrupts MRSA biofilms and inhibits the production of hemolysins.

CAS 23750-73-4

Anti-MRSA agent 27

Anti-MRSA agent 27

Ref: TM-T207164